• Home
  • Search Results
  • Humulus japonicus inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse model.

Humulus japonicus inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse model.

International journal of molecular medicine (2016-12-23)
Tae-Shin Park, Young-Kyoung Ryu, Hye-Yeon Park, Jae Yun Kim, Jun Go, Jung-Ran Noh, Yong-Hoon Kim, Jung Hwan Hwang, Dong-Hee Choi, Won-Keun Oh, Chul-Ho Lee, Kyoung-Shim Kim

Humulus japonicus Siebold & Zucc. (HJ) has traditionally been administered to patients with pulmonary disease, skin disease and hypertension in Korea, and it is considered to exert anti-inflammatory, antioxidant, antimicrobial and antimycobacterial effects. However, its effects against Alzheimer's disease (AD) have yet to be explored. Thus, this study was carried out to investigate whether HJ has a beneficial effect on the progression of AD in an animal model. A methanolic extract of HJ (500 mg/kg/day) was intragastrically administered to 5-month-old APP/PS1 transgenic (Tg-APP/PS1) mice for 2.5 months. Novel object recognition and Y-maze alteration tests were used to assess cognitive function, and an immunohistochemical assay was performed to assess amyloid β (Aβ)deposition, tau phosphorylation and gliosis. An in vitro assay using a microglial cell line was also performed to investigate the anti-inflammatory effects of HJ. Our results revealed that HJ significantly decreased the mRNA and protein expression levels of tumor necrosis factor-α (TNF‑α), interleukin (IL)-1β, IL-6 and inducible nitric oxide synthase (iNOS) induced by lipopolysaccharide in the microglial cell line. The administration of HJ for 2 months improved the cognitive function of Tg-APP/PS1 mice. HJ notably reduced the area occupied by Aβ and neurofibrillary tangles, and the number of activated astrocytes and microglia in the cortex of Tg-APP/PS1 mice. The findings of our study suggest that HJ has the therapeutic potential to inhibit the progression of AD and to improve cognitive deterioration in Tg-APP/PS1 mice.

Product Number
Product Description

Griess reagent (modified)
1-Ethyl-2-pyrrolidone, 98%
Anti-Actin Antibody, clone C4, ascites fluid, clone C4, Chemicon®
Anti-Amyloid Precursor Protein, C-Terminal antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Monoclonal Anti-Synaptophysin antibody produced in mouse, clone SVP-38, ascites fluid
Anti-NR2B Antibody, Upstate®, from rabbit
Monoclonal Anti-β-Amyloid antibody produced in mouse, clone BAM-10, ascites fluid

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.